LPCN News and Press, Lipocine Inc. From 04/11/24

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity PR Newswire LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fa...

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis PR Newswire Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52...

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 PR Newswire Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 SALT LAKE CITY , March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPC...

2024-03-07 11:17:05 ET More on Lipocine Lipocine licenses Tlando testosterone therapy to Verity Pharma Seeking Alpha’s Quant Rating on Lipocine Historical earnings data for Lipocine Financial information for Lipocine Read the full article on ...

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 PR Newswire SALT LAKE CITY , March 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today...

Lipocine to Present at 36th Annual Roth Conference PR Newswire SALT LAKE CITY , March 6, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh V...

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 PR Newswire Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK study On track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing ...

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals PR Newswire SALT LAKE CITY , Feb. 2, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) diso...

2024-01-18 08:36:41 ET More on Lipocine Seeking Alpha’s Quant Rating on Lipocine Historical earnings data for Lipocine Financial information for Lipocine For further details see: Lipocine licenses Tlando testosterone therapy to Verity Pharma

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada PR Newswire Lipocine to receive $11 million license fee Up to $259 million in development and commercial sales milestones Tiered royalties on net sales of ...